Mister Spex (MRX) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
12 May, 2026Executive summary
Achieved significant earnings improvement in Q1 2026, with adjusted EBITDA up 88% to €1.3 million, despite a 9% revenue decline to €40.7 million, reflecting restructuring, cost discipline, and a focus on margin quality.
Gross margin expanded by 234 basis points to 58.8%, driven by a higher share of prescription glasses and reduced discounting.
Offline segment outperformed with 11% revenue growth and 7% like-for-like growth, while online revenue declined 19% due to efficiency measures, price repositioning, and exit from unprofitable markets.
Strategic focus on premiumization, digital transformation, and subscription models is driving higher average order value and customer retention.
Introduced four structural enablers: unified tech stack, AI-driven automation, operating leverage, and value creation to support scalable growth.
Financial highlights
Net revenue for Q1 2026 was €40.7 million, down 9% year-over-year.
Adjusted EBITDA improved 88% year-over-year to €1.3 million, with margin rising to 3.2% of revenue.
Gross margin expanded to 58.8% (up from 56.4% year-over-year).
Cash and cash equivalents stood at €47.9 million at quarter-end, down from €56.2 million at year-end 2025.
Net loss for the period was €6.5 million, a 5% improvement year-over-year.
Outlook and guidance
Full-year 2026 guidance confirmed: net revenue growth of 0% to -10%, adjusted EBITDA margin breakeven to mid-single digits, and year-end cash of €25–30 million.
Q2 2026 will see €1.3 million in acquisition payments and a low single-digit EBITDA adjustment for transformation projects.
Moderate increase in average order value expected, supported by expanded lens offering and Switch subscription growth.
No new information indicating material changes to the forecast; impact of Iran conflict escalation remains uncertain.
Latest events from Mister Spex
- Margin expansion and structural improvements drove a €59m EBIT improvement and profitability inflection.MRX
Q4 202526 Mar 2026 - Gross margin rose to 48.8% as restructuring drove losses and international sales fell 17%.MRX
Q3 202414 Jan 2026 - Restructuring led to a 3% revenue drop and wider losses in 2024; EBIT to improve in 2025.MRX
H2 202426 Dec 2025 - Gross margin rose to 56.4% and EBIT loss narrowed, despite a 13% revenue drop.MRX
Q1 202523 Dec 2025 - Gross margin rose to 55.0% as cost discipline offset revenue declines and losses narrowed.MRX
Q2 202523 Nov 2025 - Q3 2025 revenue fell 18%, but gross margin and EBIT improved sharply amid ongoing transformation.MRX
Q3 202513 Nov 2025 - Profitability challenges prompt transformation and rebranding amid modest revenue growth.MRX
H1 202413 Jun 2025